Futuristics
Long/short equity, biotech, healthcare, small-cap

Acorda Therapeutics: Long-Term Fundamentals Look Promising

Acorda Therapeutics, Inc. (NASDAQ:ACOR) shares are trading at around $36 and generated a 16% return last year. They have the potential to deliver around a 50% return this year.

The following reasons could be cited as the potential drivers of the stock.

1. The company, like every year increased the price of its drug Ampyra by 10.75%, effective from January 2014. This price hike is consistent with the company's strategy, as it has been raising the price of Amprya in the first quarter every year. The drug improves walking in patients suffering from Multiple sclerosis (NYSE:MS). In the recently released fourth-quarter results, the drug reported revenue of $84.6 million and for the full year net revenue...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details